High thymidine kinase activity is a strong predictive factor for poor prognosis in peripheral T-cell lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone

@article{Suzuki2012HighTK,
  title={High thymidine kinase activity is a strong predictive factor for poor prognosis in peripheral T-cell lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone},
  author={Kazuhito Suzuki and Yasuhito Terui and Kenji Nakano and Eriko Nara and Kentaro Nasu and Kyoko Ueda and Noriko Nishimura and Yuko Mishima and Sakura Sakajiri and Masahiro Yokoyama and Shunji Takahashi and Kiyohiko Hatake},
  journal={Leukemia \& Lymphoma},
  year={2012},
  volume={53},
  pages={849 - 854}
}
Abstract The prognosis of patients with peripheral T-cell lymphoma (PTCL) treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) is poor, but their laboratory prognostic parameters had not previously been evaluated. We retrospectively reviewed 55 patients with newly diagnosed PTCL treated with CHOP from August 1999 to May 2009 at our institution. We analyzed six laboratory parameters, including thymidine kinase (TK) activity, to evaluate overall survival, which was the… 
3 Citations

Prognostic value of high thymidine kinase activity in patients with previously untreated diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone

High TK activity was a strong predictor for short OS and poor response among patients with previously untreated DLBCL treated with R-CHOP.

There is life in the old dog yet: thymidine kinase as predictive marker in diffuse large B-cell lymphoma

Since high TK activity correlated with inferior clinical response as well as inferior progression-free and overall survival after treatment with R-CHOP, the authors suggest that this is most likely to be due to a more malignant tumor phenotype present in a highly proliferative status of the lymphoma.

Clinical Applicability of the Proliferation Marker Thymidine Kinase 1 in Head and Neck Cancer Patients

TK1 is a tumor marker in HNC patients with the ability to assess response to therapy and high or increasing levels correlated to a poor prognosis, whereas low levels correlation to an overall increased survival.

References

SHOWING 1-10 OF 97 REFERENCES

Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U)

It is suggested that a high serum sIL-2R level predicts a poor prognosis in PTCL-U, the most common type of peripheral T-cell lymphoma.

Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma.

The measure of tumor burden proposed herein, along with LDH level, can be used for developing treatment programs, and for meaningful comparison of different treatment regimens, as well as assessment of prognosis.

Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.

Despite higher toxicity, the ACVBP regimen, used as first-line treatment for patients with poor-risk aggressive lymphoma, is superior to standard CHOP with regard to both event-free survival and overall survival.

The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma.

The data show that approximately one third of patients with PTCL in the salvage setting may enjoy prolonged survival following ASCT, provided they are transplanted in a chemosensitive disease state, and the a-IPI and beta2-microglobulin level predict the outcome after ASCT in relapsing/refractory P TCL.

CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas

The CHOP-EG regimen was found to be feasible in patients with PTCLs and a more large scale phase II or phase III study is warranted on the role of gemcitabine.

A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels.

Investigation of prognostic factors for patients with large-cell lymphoma who were entered on the same treatment protocol and who had known pretreatment serum beta 2-microglobulin (beta 2M) and lactate dehydrogenase (LDH) levels found these two serum markers defined three significantly different prognostic groups.

Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas.

Multivariate analyses placed beta-2 microglobulin among the three most influential independent variables for prediction of response rate, duration of remission and overall survival.

Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type.

  • S. KimB. Kim J. S. Kim
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2007
Ki-67 expression is predictive of prognosis, and the prognostic model may become a useful tool for predicting prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type.

Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.

In the experience, gemcitabine proved to be effective in pretreated MF and PTCLU patients, even in the long term.

Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications

Serum TK appears to have some clinical value in such solid tumors as prostate cancer, breast cancer, and small-cell lung cancer, whereas it is not a reliable marker of non-small- cell lung cancer and brain tumors.
...